Reduction of HPV infections through vaccination among at-risk urban adolescents

Vaccine

Volumn 30, Issue 37, 2012, Pages 5496-5499

  Cummings, Teresa ^a,b   Zimet, Gregory D ^a,b   Brown, Darron ^a,b   Tu, Wanzhu ^a,b   Yang, Ziyi ^a,b   Fortenberry, J Dennis ^a,b   Shew, Marcia L ^a,b  

^a Department of Pediatrics ^*  (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Adolescent; Human papillomavirus infection; Human papillomavirus vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; COHORT ANALYSIS; CONDOM; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INTERVIEW; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; URBAN POPULATION; VACCINATION; VAGINA SMEAR; VIRUS DETECTION;

ADOLESCENT; CASE-CONTROL STUDIES; COHORT STUDIES; CONDOMS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; LOGISTIC MODELS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUAL BEHAVIOR; VACCINATION; VAGINA;

EID: 84864292935     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.057     Document Type: Article

References (29)

1. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(5):271-278.
2. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(May (19)):1928-1943.
3. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(April (9518)):1247-1255.
4. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347(21):1645-1651.
5. Gavin L., MacKay A.P., Brown K., Harrier S., Ventura S.J., Kann L., et al. Sexual and reproductive health of persons aged 10-24 years - United States, 2002-2007. MMWR Surveill Summ 2009, 58(July (6)):1-58.
6. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157(February (3)):218-226.
7. Collins S., Mazloomzadeh S., Winter H., Blomfield P., Bailey A., Young L.S., et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002, 109(January (1)):96-98.
8. Orr D.P., Johnston K., Brizendine E., Katz B., Fortenberry J.D. Subsequent sexually transmitted infection in urban adolescents and young adults. Arch Pediatr Adolesc Med 2001, 155(8):947.
9. Hensel D.J., Fortenberry J.D., Orr D.P. Variations in coital and noncoital sexual repertoire among adolescent women. J Adolesc Health 2008, 42(2):170-176.
10. Tu W., Batteiger B.E., Wiehe S., Ofner S., Van Der Pol B., Katz B.P., et al. Time from first intercourse to first sexually transmitted infection diagnosis among adolescent women. Arch Pediatr Adolesc Med 2009, 163(12):1106.
11. Weaver B., Shew M., Qadadri B., Tu W., Tong Y., Denski C., et al. Natural history of multiple human papillomavirus infections in female adolescents with prolonged follow-up. J Adolesc Health 2010.
12. Gravitt P.E., Peyton C.L., Apple R.J., Wheeler C.M. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization reverse line blot detection method. J Clin Microbiol 1998, 36(October (10)):3020-3027.
13. Gravitt P.E., Peyton C.L., Alessi T.Q., Wheeler C.M., Coutlee F., Hildesheim A., et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38(1):357-361.
14. Fife K.H., Wu J.W., Squires K.E., Watts D.H., Andersen J.W., Brown D.R. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 51(July (3)):274-282.
15. Brown C.R., Leon M.L., Munoz K., Fagioni A., Amador L.G., Frain B., et al. Human papillomavirus infection and its association with cervical dysplasia in Ecuadorian women attending a private cancer screening clinic. Braz J Med Biol Res 2009, 42(July (7)):629-636.
16. Brown D.R., Shew M.L., Qadadri B., Neptune N., Vargus M., Tu W., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005, 191(2):182-192.
17. Ermel A., Qadadri B., Morishita A., Miyagawa I., Yamazaki G., Weaver B., et al. Human papillomavirus detection and typing in thin prep cervical cytologic specimens comparing the digene hybrid capture II assay, the roche linear array hpv genotyping assay, and the kurabo genesquare microarray assay. J Virol Methods 2010, 169(1):154-161.
18. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(October (19)):1444-1451.
19. Tarkowski T.A., Koumans E.H., Sawyer M., Pierce A., Black C.M., Papp J.R., et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 2004, 189(January (1)):46-50.
20. Dunne E.F., Sternberg M., Markowitz L.E., McQuillan G., Swan D., Patel S., et al. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States - National Health and Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact?. J Infect Dis 2011, 204(August (4)):562-565.
21. Brabin L., Roberts S.A., Stretch R., Baxter D., Chambers G., Kitchener H., et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008, 336(May (7652)):1056-1058.
22. Ogilvie G.S., Remple V.P., Fawziah M., McNeil S.A., Monika N., Karen L.P., et al. Parental intention to have daughters receive the human papillomavirus vaccine. Can Med Assoc J 2007, 177(December (12)):1506-1512.
23. Schuler C.L., Reiter P.L., Smith J.S., Brewer N.T. Human papillomavirus vaccine and behavioural disinhibition. Sex Transm Infect 2011, 87(June (4)):349-353.
24. Brewer N.T., Cuite C.L., Herrington J.E., Weinstein N.D. Risk compensation and vaccination: can getting vaccinated cause people to engage in risky behaviors?. Ann Behav Med 2007, 34(August (1)):95-99.
25. Marlow L.A., Forster A.S., Wardle J., Waller J. Mothers' and adolescents' beliefs about risk compensation following HPV vaccination. J Adolesc Health 2009, 44(May (5)):446-451.
26. Mullins T.L., Zimet G.D., Rosenthal S.L., Morrow C., Ding L., Shew M., et al. Adolescent perceptions of risk and need for safer sexual behaviors after first human papillomavirus vaccination. Arch Pediatr Adolesc Med 2012, 166(January (1)):82-88.
27. Liddon N.C., Leichliter J.S., Markowitz L.E. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med 2012, 42(January (1)):44-52.
28. Trends in HIV- and STD-Related Risk Behaviors Among High School Students-United States, 1991-2007. JAMA 2008, 300(October (14)):1643-1645.
29. Manhart L.E., Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia?: a meta-analysis. Sex Transm Dis 2002, 29(11):725.